Interpace Diagnostics Group Inc (IDXG) Sees Coverage Initiated By Ladenburg with a $2.2500 Price

June 24, 2018 - By reb123z

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Logo

Why Has Ladenburg Given Interpace Diagnostics Group Inc (IDXG) a $2.2500 Price Target

Ladenburg analyst initiated coverage with a “Buy” rating on Interpace Diagnostics Group Inc (IDXG) today and set a price target of $2.2500. The firm’s shares opened today at 0.9.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Ratings Coverage

Among 3 analysts covering Interpace Diagnostics Gr (IDXG), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Interpace Diagnostics Gr has $4.5 highest and $2.25 lowest target. $3.25’s average target is 261.11% above currents $0.9 stock price. Interpace Diagnostics Gr had 7 analyst reports since February 22, 2018 according to SRatingsIntel. H.C. Wainwright maintained Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) on Friday, March 16 with “Buy” rating. The firm earned “Buy” rating on Friday, April 6 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, June 12 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Friday, May 11.

The stock increased 4.65% or $0.04 during the last trading session, reaching $0.9. About 656,025 shares traded or 127.20% up from the average. Interpace Diagnostics Group, Inc. (IDXG) has declined 55.08% since June 24, 2017 and is downtrending. It has underperformed by 67.65% the S&P500.

Analysts await Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) to report earnings on August, 9. They expect $-0.08 earnings per share, up 87.69 % or $0.57 from last year’s $-0.65 per share. After $-0.11 actual earnings per share reported by Interpace Diagnostics Group, Inc. for the previous quarter, Wall Street now forecasts -27.27 % EPS growth.

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company has market cap of $25.08 million. The firm offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. It currently has negative earnings. The Company’s clients consist primarily of physicians, hospitals, and clinics.

More notable recent Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) news were published by: Streetinsider.com which released: “Interpace Diagnostics (IDXG) Announces Coverage of Thyroid Testing by Blue Cross Blue Shield of Florida” on June 11, 2018, also Streetinsider.com with their article: “Ladenburg Thalmann Starts Interpace Diagnostics Group Inc (IDXG ) at Buy” published on June 22, 2018, Globenewswire.com published: “Interpace Diagnostics Presents New Data on PancraGEN® at Digestive Disease Week” on June 01, 2018. More interesting news about Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) were released by: Nasdaq.com and their article: “Interpace Diagnostics to Attend and Present at the 8th Annual LD Micro Invitational Conference” published on June 04, 2018 as well as Globenewswire.com‘s news article titled: “Interpace Diagnostics Enters into Agreement with Nationally Renowned Institution” with publication date: May 30, 2018.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: